ReviewCureus2022
The Role of Gut-Microbiota in the Pathophysiology and Therapy of Irritable Bowel Syndrome: A Systematic Review.
Review in Cureus, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 2 syntheses or guidelines pooled it, 39 citations in OpenAlex.
- A bibliometric analysis of global research status and trends in irritable bowel syndrome and gut microbiota metabolites.Frontiers in microbiology · 2025Pooled it
- Global research states and trends of micro RNA in irritable bowel syndrome: a bibliometric analysis.Clinical and experimental medicine · 2024Pooled it
- Efficacy and dose response ofWorld journal of gastroenterology · 2023Trial
- Investigation of the Effect of Akkermansia muciniphila Muc T (ATCC BAA-835) on TLR4/NF-Kappa B/NLRP2 Signaling Pathway and Intestinal Microbiota in Diarrhea-Predominant Irritable Bowel Syndrome in Rats.Probiotics and antimicrobial proteins · 2026Article
- Pathophysiology-driven use of natural products in irritable bowel syndrome: a review.Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
- Metformin as a Multifaceted Therapeutic Agent for Gastrointestinal Diseases: Mechanisms, Clinical Efficacy, and Future Directions.Pharmacology research & perspectives · 2026Review
- Engineering bacteriophages for gut health: precision antimicrobials and beyond.Journal of nanobiotechnology · 2026Review
- Depressive symptoms as a mediator in the association between regular physical activity and irritable bowel syndrome-related symptom severity: a cross-sectional study among college students.Frontiers in psychology · 2026Article
- Lessons from irritable bowel syndrome: potential for understanding and managing post-COVID.Frontiers in immunology · 2026Review
- Histamine-Producing Intestinal Dysbiosis and Its Role in Lower Urinary Tract Infections and Irritable Bowel Syndrome in Young Women.Nutrients · 2025Article
- Prediction of irritable bowel syndrome by integrating urine metabolites and gut microbiota.Scientific reports · 2025Article
- Resistant Starch and Microbiota-Derived Secondary Metabolites: A Focus on Postbiotic Pathways in Gut Health and Irritable Bowel Syndrome.International journal of molecular sciences · 2025Review
- Psycho-gastroenterological profile of an Italian population of children with disorders of gut-brain interaction: A case-control study.World journal of clinical pediatrics · 2025Article
- Management of Fibromyalgia: Novel Nutraceutical Therapies Beyond Traditional Pharmaceuticals.Nutrients · 2025Review
- Impact of Microbiota on Irritable Bowel Syndrome Pathogenesis and Management: A Narrative Review.Medicina (Kaunas, Lithuania) · 2025Review
- Crohn's disease, irritable bowel syndrome, and chronic fatigue: the importance of communication and symptom management-a case report.Journal of medical case reports · 2025Article
- The effect of Massa Medicata Fermentata on the cytokine secretion of colonic mucosa and visceral sensitivity in rats with IBS-D.Frontiers in cellular and infection microbiology · 2025Article
- Association of intestinal mucosal barrier function with intestinal microbiota in Spleen-Kidney Yang Deficiency IBS-D mice.Frontiers in microbiology · 2025Article
- From Inflammasomes to Pyroptosis: Molecular Mechanisms in Chronic Intestinal Diseases - Opportunity or Challenge?Journal of inflammation research · 2025Review
- Wuling powder ameliorates diarrhea-predominant irritable bowel syndrome in mice by modulating gut mucosal microbiota and alleviating intestinal inflammation.Frontiers in cellular and infection microbiology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Irritable Bowel Syndrome (IBS) is one of the most prevalent chronic gastrointestinal diseases, which is characterized by recurrent abdominal pain and altered bowel habits. The pathophysiological mechanisms are not completely clear for IBS, multiple factors such as genetic, psychosocial, environmental, visceral hypersensitivity, low-grade inflammation, gastrointestinal motility changes, food components, and intestinal microbiota are thought to play a role in the disease process of IBS. The rapid progression of recent microbiome research using advanced microbiological technologies has shed light on dysbiosis related to the pathophysiology of IBS. We used PubMed, PubMed Central, and Medline as our primary databases to search for articles using keywords and medical subject heading (MeSH) keywords on April 30, 2022, to render a total of 4062 articles. Then, a total of 10 articles were selected following a quality assessment. Despite the variable findings in different studies, most studies have concluded that IBS patients have a reduction in bacterial diversity and an increase in the temporal instability of the microbiota. IBS is known as a
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.